Temporary order concerning reduced tax rates for dividends received by substantial shareholders
The full update (in Hebrew) is available through the PDF icon.
Meitar represented Neuroderm (Nasdaq: NDRM), a company engaged in developing treatments for diseases related to the central nervous system, in a $75 million follow-on public offering.
An article by Meitar partner Dr. Yoav Oestreicher, describing what a trade secret is and when its use is considered a violation.
For the full article published at “Haaretz” (Hebrew), please click here.